Toggle Mobile Navigation

Pfizer in Hot Water With FDA Over ESTRING Ad

A recent advertisement for Pfizer‘s new hormonal therapy for postmenopausal patients, Estring, caught the attention of the FDA‘s Office of Prescription Drug Promotion in a bad way. In this direct-to-consumer promotion, spokespeople for Estring, depicted in the ad as doctor and patient, discuss the new treatment, with the patient proclaiming that she had suffered no side effects. Unfortunately for Pfizer, any plausible side effects must be brought to the attention of consumers, even if this particular case showed none. This resulted in a chastising letter for Pfizer.

Though Pfizer might not agree, this story also confirms some good news in the industry. This letter was only the second sent out this year to a company from FDA’s Office of Prescription Drug Promotion.

Our friends over at FiercePharma go into more detail regarding this Pfizer slip-up and more. Read the full article over on FiercePharma now!

To help keep the number of letters down to a minimum by avoiding your own letter from the “ad police,” you should think about attending ExL Events‘ upcoming 6th Promotional Review Committee Compliance & Best Practices conference on September 24–26 in Morristown, NJ. This conference is the only industry event specifically devoted to selecting and training the best possible team members for your PRC and also making sure they can collaborate smoothly. No other event goes into as much depth on both the technical regulatory requirements and operational needs for promotional review professionals.

posted in Healthcare, Pharmaceutical, Public/Government Relations, Quality

live chat software